Advances in Pediatric Hodgkin Lymphoma with an Eye on Disparities and Vulnerable Populations.

Advances in pediatric and adolescent young adult Hodgkin lymphoma (HL), including the incorporation of targeted therapy and immunotherapy have resulted in excellent cure rates with survival greater than 90%, including patients with advanced stage disease. Current trials seek to maintain excellent survival while reducing acute and long-term toxicities. Despite these successes, vulnerable patient populations, including Black, Hispanic, and adolescent young adult patients, continue to have inferior outcomes. This article reviews recent therapeutic advances in HL, summarizes therapeutic gaps, and highlights opportunities to improve outcomes in patients with social and economic disparities.